Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Amylyx Pharmaceuticals reported its third-quarter 2026 financial results, highlighting positive topline data from the Phase 3 LUCIDITY trial of avexitide and a strengthened balance sheet.
Amylyx Pharmaceuticals announced it will host an investor event at the upcoming ObesityWeek® 2026 conference, featuring experts in post-bariatric hypoglycemia (PBH).
Amylyx Pharmaceuticals announced its participation in upcoming investor conferences scheduled for November 2026.
Amylyx Pharmaceuticals has scheduled the release of its financial results for the third quarter of 2026 for November 5, 2026.
Citigroup analyst Geoff Meacham maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $32 to $39.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17,